Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2024-2028
The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market size is estimated to grow by USD 88.18 million at a CAGR of 5.54% between 2023 and 2028.
There is an increase in the number of strategic alliances formed due to collaborations and license agreements are expected to help co-develop and commercialize PI3K inhibitors globally. In addition, co-development agreements enable the use of the technical expertise of both companies, which, in turn, would help them promote and support each other to develop and market novel drugs. Moreover, such agreements also ensure the in-flow of adequate funds for the companies involved and reduce liability costs incurred by individual companies in case of failures, thereby attracting more venture investments. Hence, such factors are positively impacting the market.
Technavio has segmented the market into Application, Distribution Channel, and Geography
- The application segment is classified into CLL, FL, and other indications.
- The distribution channel segment is classified into hospital pharmacies, retail pharmacies, and online pharmacies
- The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.
What will be the Size of the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market During the Forecast Period?
_inhibitors_market_size_abstract_2024_v1.jpg)
To learn more about this report, Download Report Sample
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation by Application, Distribution Channel, and Geography Analysis
Application Analysis
CLL
The CLL segment is estimated to witness significant growth during the forecast period. The chronic lymphocytic leukemia (CLL) segment of the global PI3K inhibitors market comprises SLL, as CLL and SLL come under the same category of lymphomas. In addition, in CLL, cancer cells are found mostly in the blood and bone marrow, whereas in SLL, cancer cells are found mostly in the lymph nodes. Even though only half of the PI3K inhibitors are approved for CLL, it was the major application in the global PI3K inhibitors market.
_inhibitors_market_segments_abstract_2024_v2.jpg)
Get a glance at the market contribution of various segments Download PDF Sample
The CLL segment was the largest segment and was valued at USD 99.04 million in 2018. Moreover, the growth of this segment can be primarily attributed to the higher prevalence of CLL and SLL than FL globally. For example, according to the National Institutes of Health (NIH), the prevalence rate of CLL in 2022 was 25% to 30% of leukemias, and about 20,160 people had CLL in the US. In addition, the number of new cancer cases has increased significantly in recent years, owing to factors such as the increasing geriatric population and the increasing exposure to hazardous chemicals. Thus, several companies are conducting extensive research on developing novel therapeutics, such as PI3K inhibitors, to capture the huge unmet need. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
Distribution Channel Analysis
Hospital pharmacies
The hospital pharmacies segment essentially serves as a liaison between pharmaceutical companies and healthcare providers, guaranteeing that PI3K inhibitors are available on hospital grounds. In addition, as PI3K inhibitors need close monitoring during treatment and their administration is complicated, this distribution model is especially pertinent to them. Moreover, hospitals are the major care settings for patients with cancer, and having these inhibitors on-site guarantees prompt access to necessary drugs. Furthermore, the specialized character of PI3K inhibitors and hospital chemists' experience managing complex medications complement each other, enhancing therapeutic efficacy and safety overall. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.
Retail pharmacies
Retail pharmacies offer accessibility and convenience for patients looking for PI3K inhibitors, making them a vital distribution channel. In addition, the understanding that many patients prefer getting their prescriptions filled at neighborhood pharmacies because of things like convenience, accessibility, pharmacy automation and individualized care is the foundation for this channel segmentation. Moreover, pharmacists with training who work in retail pharmacies can provide helpful advice and information on how to use PI3K inhibitors correctly. Furthermore, the retail pharmacy market offers a venue for raising consumer awareness and education. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period
Regional Analysis
_inhibitors_market_regions_abstract_2023_geo_v2.jpg)
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The growth of the market in North America is fuelled by the sales of approved PI3K inhibitors and the increasing prevalence of several cancer indications, such as CLL, FL, and breast cancer. As per BreastCancer.org, there were more than 3.5 million women in the US with a history of breast cancer in January 2020, and breast cancer death rates were greater than any other malignancy. Moreover, NSCLC and breast cancer are two of the most prevalent types of cancer in North America. Therefore, such a high prevalence of cancer demands advanced and specialized treatment options. Furthermore, targeted therapies such as PI3K inhibitors have the potential to meet this requirement. Therefore, the high prevalence of cancer indications is expected to drive the growth of the market in North America during the forecast period
Key Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 14 market companies, including:
Bayer AG: The company offers phosphoinositide 3 kinase inhibitor namely Copanlisib.
- AbbVie Inc.
- Celon Pharma SA
- Curis Inc.
- Eli Lilly and Co.
- Exelixis Inc.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- Merck KGaA
- Molecular Depot LLC
- Novartis AG
- TG Therapeutics Inc.
- Verastem Inc.
- Secura Bio Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Key Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Drivers
One of the key factors driving the phosphoinositide 3-kinase (PI3K) inhibitors market growth is the recent approvals of blood therapies. Even though several approved therapies are available for different types of blood cancer, the market experiences a huge unmet need for their treatment. In addition, many chemotherapy drugs are dominating the treatment landscape for several types of cancer, including lymphomas. However, chemotherapies have some limitations, which minimize patient adherence to the treatment.
Therefore, cancer treatment is experiencing a shift from traditional chemotherapy drugs to targeted therapies. In addition, the pharmacokinetics and pharmacodynamics of the treatment landscape for advanced or metastatic lymphomas, such as CLL, SLL, and FL, still have a scope for improvement. Hence such factors, through exhaustive research, targeted therapies such as PI3K inhibitors with proven efficacy in oncology applications are developed as suitable solutions for cancer treatment. Therefore, such factors are positively impacting the phosphoinositide 3-kinase inhibitor market. Hence, it is expected to drive the market growth during the forecast period.
Significant Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Trends
A key trend shaping the phosphoinositide 3-kinase (PI3K) inhibitors market growth is the rising adoption of reimbursement programs. In oncology treatment in the small molecules targeted therapy category, PI3K inhibitors are relatively new. In addition, the cost of these drugs is usually high, primarily due to the complex manufacturing process, which was a major challenge faced by the global PI3K inhibitors market for a long time.
Moreover, to overcome this challenge, various governments have come up with patient assistance programs to reduce the cost burden on patients and make them available at an affordable price. For example, Patient Protection and Affordable Care is an initiative taken by the US government that works to provide affordable health insurance. Therefore, such factors are positively impacting the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market. Hence, it is expected to drive the market growth during the forecast period.
Major Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Challenges
Low adoption of therapeutic drugs is one of the key challenges hindering the phosphoinositide 3-kinase (PI3K) inhibitors market growth. PI3K inhibitor drugs exhibit strong adverse effects associated with the treatment of various indications. In addition, while PI3K inhibitors are often considered safe, the treatment using these drugs could cause severe adverse effects in some patients.
Moreover, a major share of the side effects in most of the patients are mild, such as swelling in the arms, hands, and legs; skin rashes; anemia; and infusion reactions. In addition in some cases, the side effects are very severe and could be life-threatening. Furthermore, these side effects also result in patients switching to alternative therapeutics for the treatment. Therefore, such factors are negatively impacting the phosphoinositide 3-kinase inhibitor market. Hence, it is expected to hinder the market growth during the forecast period.
Key Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Customer Landscape
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
_inhibitors_market_customer_landscape_abstract_2023_geo_v1.jpg)
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Customer Landscape
Segment Overview
The phosphoinositide 3-kinase (PI3K) inhibitors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
- Application Outlook
- CLL
- FL
- Other indications
- Distribution Channel Outlook
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Geography Outlook
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- Rest of the World (ROW)
- Australia
- Argentina
- Brazil
- North America
|
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
163 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.54% |
|
Market Growth 2024-2028 |
USD 88.18 million |
|
Market structure |
Concentrated |
|
YoY growth 2023-2024(%) |
4.48 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Bayer AG, Celon Pharma SA, Curis Inc., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Merck KGaA, Molecular Depot LLC, Novartis AG, TG Therapeutics Inc., Verastem Inc., and Secura Bio Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
What are the Key Data Covered in this Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the PI3K inhibitors market between 2024 and 2028
- Precise estimation of the PI3K inhibitors market size and its contribution to the market in focus on the parent market
- Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
- Companies landscape comparing criticality of inputs and factors of differentiation
- Exclusive Matrix on companies position and classification
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of phosphoinositide 3-kinase (PI3K) inhibitors market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch